title: [Evaluation of the influence of tianeptine on the psychosomatic status of patients with ulcerative colitis in remission].
abstract: In order to maintain ulcerative colitis (UC) in remission, chronic use of aminosalicylates is recommended. All patients have a fear of the recurrence of symptoms, which makes their mental state and quality of life worse. Because of this a number of patients are recommended to use different sorts of anxiolytic drugs and antidepressants.
  
  
  OBJECTIVE
  Evaluation of the influence of tianeptine (selective serotonin reuptake enhancer) on the mental and somatic status in the group of patients.
  
  
  METHODS
  The research was conducted in two groups of thirty patients, with benign form of ulcerative colitis in remission, aged 24-46 years. Patients, during a period of 12 months, were given aminosalicylates in a daily doses 2 x 1.0 g and tianeptine in a doses 3 x 12.5 mg (group I) or placebo (group II). During the treatment every three months anxiety (Hamilton Anxiety Rating Scale-HARS), depression (Back Depression Inventory-BDI), The Mayo Clinic Disease Activity Index (MCDAI), hemoglobin and C-reactive protein (CRP) level were evaluated.
  
  
  RESULTS
  After 12 months in a group of patients who took tianeptine decrease in anxiety (from 20.35 +/- 4.03 to 12.65 +/- 3.78 points) and depression (from 19.95 +/- 4.49 points to 9.60 +/- 2.76 points) was obtained; difference compared with placebo was statistically significant (p < 0.01). At the same time significant decrease compared with placebo (p < 0.05) of disease activity index (respectively 3.05 +/- 1.36 and 4.65 +/- 1.69), insignificantly lower level of CRP (7.00 5.65 and 9.41 +/- 10.12) and higher level of hemoglobin (11.93 +/- 0.83 and 11.0 +/- 0.70) was observed.
  
  
  CONCLUSIONS
  Tianeptine has a positive influence on mental and somatic status of patients with UC. Results give the support for tianeptine apllication in UC as adjuvant drug.
authors.affiliation: Uniwersytet Medyczny w Łodzi, Klinika Gastroenterologii.
authors.forename: Cezary
authors.initials: C
authors.lastname: Chojnacki
authors.forename: Ewa
authors.initials: E
authors.lastname: Walecka-Kapica
authors.forename: Grazyna
authors.initials: G
authors.lastname: Klupinska
authors.forename: Monika
authors.initials: M
authors.lastname: Pawłowicz
authors.forename: Antoni
authors.initials: A
authors.lastname: Florkowski
authors.forename: Patrycja
authors.initials: P
authors.lastname: Wachowska-Kelly
authors.forename: Jan
authors.initials: J
authors.lastname: Chojnacki
mesh_terms: D000328:Adult; D010131:Aminosalicylic Acid / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001007:Anxiety / Q000188:drug therapy* / Q000209:etiology; D003093:Colitis, Ulcerative / Q000150:complications* / Q000188:drug therapy; D003863:Depression / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D013841:Thiazepines / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000929:Antidepressive Agents, Tricyclic; D013841:Thiazepines; C050504:tianeptine; D010131:Aminosalicylic Acid